Abstract
Acute myeloid leukemia (AML) is a cancer that originates from the bone marrow (BM). Under physiological conditions, the bone marrow supports the homeostasis of immune cells and hosts memory lymphoid cells. In this review, we summarize our present understanding of the role of the immune microenvironment on healthy bone marrow and on the development of AML, with a focus on T cells and other lymphoid cells. The types and function of different immune cells involved in the AML microenvironment as well as their putative role in the onset of disease and response to treatment are presented. We also describe how the immune context predicts the response to immunotherapy in AML and how these therapies modulate the immune status of the bone marrow. Finally, we focus on allogeneic stem cell transplantation and summarize the current understanding of the immune environment in the post-transplant bone marrow, the factors associated with immune escape and relevant strategies to prevent and treat relapse.
Original language | English |
---|---|
Article number | 100991 |
Journal | Blood Reviews |
Volume | 57 |
DOIs | |
Publication status | Published - Jan 2023 |
Bibliographical note
Acknowledgements:The authors are grateful for support from the Montreal Cancer Consortium (Terry Fox Research Institute – Grant #1084). The authors also thank Wallonie-Bruxelles International for the financial support (WBI world excellence scholarship allocated to YS). JSD,FM and SA are current holders of Fonds de recherche du Québec – Santé (FRQS) career awards and JSD is a member of the Quebec network of cell, tissue and gene therapy (ThéCell) and of the Canadian Donation and Transplant Research Program (CDTRP). We acknowledge all colleagues of the hematology departments of the Hôpital Maisonneuve-Rosemont in Montreal and of the Erasmus medical center in Rotterdam for fruitful discussions. We apologize to all colleagues whose work could not be cited in this review due to lack of space.
Publisher Copyright: © 2022 The Authors